Abstract
Chronic kidney disease (CKD) is the main cause of end-stage renal disease worldwide arising as a frequent complication of diabetes, obesity, and hypertension. Current therapeutic options, mainly based of inhibition of the renin-angiotensin system (RAS), provide imperfect renoprotection if started at an advanced phase of the disease, and treatments that show or even reverse the progression of CKD are needed. The endothelin (ET) system contributes to the normal renal physiology; however, robust evidence suggests a key role of ET-1 and its cognate receptors, in the progression of CKD. The effectiveness of ET receptor antagonists in ameliorating renal hemodynamics and fibrosis has been largely demonstrated in different experimental models. A significant antiproteinuric effect of ET receptor antagonists has been found in diabetic and non-diabetic CKD patients even on top of RAS blockade, and emerging evidence from ongoing clinical trials highlights their beneficial effects on a wide range of kidney disorders.
Similar content being viewed by others
References
Yanagisawa M, Kurihara H, Kimura S et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415
Kohan DE, Barton M (2014) Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 86:896–904
Neuhofer W, Pittrow D (2009) Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur J Clin Investig 39(Suppl 2):50–67
Barton M, Yanagisawa M (2008) Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 86:485–498
Ruggenenti P, Perna A, Remuzzi G, Gruppo Italiano di Studi Epidemiologici in Nefrologia (2001) ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 12:2832–2837
Inoue A, Yanagisawa M, Kimura S et al (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 86:2863–2867
Longaretti L, Benigni A (2009) Endothelin receptor selectivity in chronic renal failure. Eur J Clin Investig 39(Suppl 2):32–37
Kuc R, Davenport AP (2004) Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. J Cardiovasc Pharmacol 44(Suppl 1):S224–S226
Wendel M, Knels L, Kummer W, Koch T (2006) Distribution of endothelin receptor subtypes ETA and ETB in the rat kidney. J Histochem Cytochem 54:1193–1203
Kohan DE, Pritchett Y, Molitch M et al (2011) Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22:763–772
Cybulsky AV, Stewart DJ, Cybulsky MI (1993) Glomerular epithelial cells produce endothelin-1. J Am Soc Nephrol 3:1398–1404
Sorokin A, Kohan DE (2003) Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Ren Physiol 285:F579–F589
Kohan DE (2009) Biology of endothelin receptors in the collecting duct. Kidney Int 76:481–486
Ahn D, Ge Y, Stricklett PK et al (2004) Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 114:504–511
Gariepy CE, Ohuchi T, Williams SC et al (2000) Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 105:925–933
Ge Y, Huang Y, Kohan DE (2008) Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure. Can J Physiol Pharmacol 86:329–336
Ge Y, Bagnall A, Stricklett PK et al (2006) Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Ren Physiol 291:F1274–F1280
Kohan DE, Rossi NF, Inscho EW, Pollock DM (2011) Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91:1–77
Ge Y, Stricklett PK, Hughes AK et al (2005) Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol Ren Physiol 289:F692–F698
Ge Y, Bagnall A, Stricklett PK et al (2008) Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol Ren Physiol 295:F1635–F1640
Bugaj V, Pochynyuk O, Mironova E et al (2008) Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct. Am J Physiol Ren Physiol 295:F1063–F1070
Stricklett PK, Hughes AK, Kohan DE (2006) Endothelin-1 stimulates NO production and inhibits cAMP accumulation in rat inner medullary collecting duct through independent pathways. Am J Physiol Ren Physiol 290:F1315–F1319
Sullivan JC, Goodchild TT, Cai Z et al (2007) Endothelin(A) (ET(A)) and ET(B) receptor-mediated regulation of nitric oxide synthase 1 (NOS1) and NOS3 isoforms in the renal inner medulla. Acta Physiol (Oxford) 191:329–336
Benigni A, Cassis P, Remuzzi G (2010) Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2:247–257
Wolf G, Haberstroh U, Neilson EG (1992) Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140:95–107
Kohno M, Horio T, Ikeda M et al (1992) Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int 42:860–866
Barton M, Shaw S, d’Uscio LV et al (1997) Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 238:861–865
Moreau P, d’Uscio LV, Shaw S et al (1997) Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 96:1593–1597
Wenzel RR, Rüthemann J, Bruck H et al (2001) Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man. Br J Clin Pharmacol 52:151–157
Rossi GP, Ganzaroli C, Cesari M et al (2003) Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovasc Res 57:277–283
Benigni A, Perico N, Gaspari F et al (1991) Increased renal endothelin production in rats with reduced renal mass. Am J Phys 260:F331–F339
Bruzzi I, Corna D, Zoja C et al (1997) Time course and localization of endothelin-1 gene expression in a model of renal disease progression. Am J Pathol 151:1241–1247
Zoja C, Benigni A, Camozzi D et al (2003) Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. Kidney Int 64:857–863
Nakamura T, Ebihara I, Fukui M et al (1993) Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice. Ren Physiol Biochem 16:233–243
Benigni A, Colosio V, Brena C et al (1998) Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47:450–456
Benigni A, Zoja C, Corna D et al (1993) A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44:440–444
Barton M (2010) Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochim Biophys Acta 1802:1203–1213
Vaněčková I, Hojná S, Kadlecová M et al (2018) Renoprotective effects of ET(A) receptor antagonists therapy in experimental non-diabetic chronic kidney disease: is there still hope for the future? Physiol Res 67:S55–S67
Morigi M, Buelli S, Angioletti S et al (2005) In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 166:1309–1320
Collino F, Bussolati B, Gerbaudo E et al (2008) Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Ren Physiol 294:F1185–F1194
Saleh MA, Boesen EI, Pollock JS et al (2010) Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 56:942–949
Buelli S, Rosanò L, Gagliardini E et al (2014) β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. J Am Soc Nephrol 25:523–533
Morigi M, Buelli S, Zanchi C et al (2006) Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 169:1965–1975
Soroka S, Alam A, Bevilacqua M et al (2017) Assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease: a Canadian expert consensus. Can J Kidney Health Dis 4:2054358117695784
Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76:149–168
Reiterová J, Merta M, Stekrová J et al (2007) The influence of endothelin-A receptor gene polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy. Folia Biol (Praha) 53:134–137
Reiterová J, Merta M, Stekrová J et al (2006) Influence of endothelin-1 gene polymorphisms on the progression of autosomal dominant polycystic kidney disease. Kidney Blood Press Res 29:182–188
Ong AC, Jowett TP, Firth JD et al (1995) An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int 48:390–401
Ong AC, Jowett TP, Firth JD et al (1994) Human tubular-derived endothelin in the paracrine regulation of renal interstitial fibroblast function. Exp Nephrol 2:134
Munemura C, Uemasu J, Kawasaki H (1994) Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: possible evidence of heterogeneity in cystogenesis. Am J Kidney Dis 24:561–568
Chang M-Y, Parker E, El Nahas M et al (2007) Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18:560–569
Hocher B, Thöne-Reineke C, Rohmeiss P et al (1997) Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99:1380–1389
Hocher B, Kalk P, Slowinski T et al (2003) ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease. J Am Soc Nephrol 14:367–376
Daina E, Cravedi P, Alpa M et al (2015) A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study. Nephron 130:13–20
Savige J (2014) Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment. J Physiol Lond 592:4013–4023
Abrahamson DR (2016) Steps on the Alport path to proteinuria. Kidney Int 90:242–244
Dufek B, Meehan DT, Delimont D et al (2016) Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease. Kidney Int 90:300–310
Nath KA, Hebbel RP (2015) Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol 11:161–171
Chaar V, Tarer V, Etienne-Julan M et al (2006) ET-1 and ecNOS gene polymorphisms and susceptibility to acute chest syndrome and painful vaso-occlusive crises in children with sickle cell anemia. Haematologica 91:1277–1278
Sabaa N, de Franceschi L, Bonnin P et al (2008) Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 118:1924–1933
Kasztan M, Fox BM, Speed JS et al (2017) Long-term endothelin-A receptor antagonism provides robust renal protection in humanized sickle cell disease mice. J Am Soc Nephrol 28:2443–2458
Taylor C, Kasztan M, Tao B et al (2019) Combined hydroxyurea and ETA receptor blockade reduces renal injury in the humanized sickle cell mouse. Acta Physiol (Oxford) 225:e13178
Cravedi P, Kopp JB, Remuzzi G (2013) Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant 13:266–274
Chen HC, Guh JY, Chang JM et al (2001) Plasma and urinary endothelin-1 in focal segmental glomerulosclerosis. J Clin Lab Anal 15:59–63
Lattmann T, Shaw S, Münter K et al (2005) Anatomically distinct activation of endothelin-3 and the L-arginine/nitric oxide pathway in the kidney with advanced aging. Biochem Biophys Res Commun 327:234–241
Campbell KN, Tumlin JA (2018) Protecting podocytes: a key target for therapy of focal segmental glomerulosclerosis. Am J Nephrol 47(Suppl 1):14–29
Ortmann J, Amann K, Brandes RP et al (2004) Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 44:974–981
Daehn I, Casalena G, Zhang T et al (2014) Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest 124:1608–1621
Ebefors K, Wiener RJ, Yu L et al (2019) Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells. Kidney Int 96:957–970
Schieppati A, Remuzzi G (2008) Novel therapies of lupus nephritis. Curr Opin Nephrol Hypertens 17:156–161
Yoshio T, Masuyama J, Mimori A et al (1995) Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 54:361–365
Dhaun N, Lilitkarntakul P, Macintyre IM et al (2009) Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Ren Physiol 296:F1477–F1483
Herman WH, Emancipator SN, Rhoten RL, Simonson MS (1998) Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Phys 275:F8–F17
Simonson MS, Wann S, Mené P et al (1989) Endothelin stimulates phospholipase C, Na+/H+ exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 83:708–712
Nakamura T, Ebihara I, Tomino Y, Koide H (1995) Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 47:481–489
Tycová I, Hrubá P, Maixnerová D et al (2018) Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis. Physiol Res 67:93–105
Maixnerová D, Merta M, Reiterová J et al (2007) The influence of three endothelin-1 polymorphisms on the progression of IgA nephropathy. Folia Biol (Praha) 53:27–32
Lehrke I, Waldherr R, Ritz E, Wagner J (2001) Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol 12:2321–2329
Chen HC, Guh JY, Chang JM, Lai YH (2001) Differential effects of FMLP-activated neutrophils from patients with IgA nephropathy enhanced endothelin 1 production of glomerular mesangial cells. Nephron 89:274–279
Nakamura T, Ebihara I, Fukui M et al (1996) Effect of a specific endothelin receptor A antagonist on glomerulonephritis of ddY mice with IgA nephropathy. Nephron 72:454–460
Remuzzi G, Schieppati A, Ruggenenti P (2002) Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 346:1145–1151
Benigni A, Corna D, Maffi R et al (1998) Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 54:353–359
Čertíková Chábová V, Vernerová Z, Kujal P et al (2014) Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats. Life Sci 118:297–305
Amann K, Simonaviciene A, Medwedewa T et al (2001) Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J Am Soc Nephrol 12:2572–2584
Sedláková L, Čertíková Chábová V, Doleželová Š et al (2017) Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Hypertens 39:183–195
Zoja C, Zanchi C, Benigni A (2015) Key pathways in renal disease progression of experimental diabetes. Nephrol Dial Transplant 30(Suppl 4):iv54–iv59
Hocher B, Schwarz A, Reinbacher D et al (2001) Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87:161–169
Cosenzi A, Bernobich E, Trevisan R et al (2003) Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol 42:752–756
Xu M, Dai D-Z, Dai Y (2009) Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats. Am J Nephrol 29:252–256
Idris-Khodja N, Ouerd S, Mian MOR et al (2016) Endothelin-1 overexpression exaggerates diabetes-induced endothelial dysfunction by altering oxidative stress. Am J Hypertens 29:1245–1251
Watson AMD, Li J, Schumacher C et al (2010) The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 53:192–203
Sasser JM, Sullivan JC, Hobbs JL et al (2007) Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18:143–154
Spires D, Poudel B, Shields CA et al (2018) Prevention of the progression of renal injury in diabetic rodent models with preexisting renal disease with chronic endothelin A receptor blockade. Am J Physiol Ren Physiol 315:F977–F985
Gagliardini E, Corna D, Zoja C et al (2009) Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Ren Physiol 297:F1448–F1456
Lenoir O, Milon M, Virsolvy A et al (2014) Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol 25:1050–1062
Wang H, Feng Z, Xie J et al (2018) Podocyte-specific knockin of PTEN protects kidney from hyperglycemia. Am J Physiol Ren Physiol 314:F1096–F1107
Zoja C, Cattaneo S, Fiordaliso F et al (2011) Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Ren Physiol 301:F1114–F1123
Gross M-L, El-Shakmak A, Szábó A et al (2003) ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 46:856–868
Weber MA, Black H, Bakris G et al (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374:1423–1431
Bakris GL, Lindholm LH, Black HR et al (2010) Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 56:824–830
Idorsia: Drug discovery and clinical development. https://www.idorsia.com/documents/com/fact-sheets-presentations/fs-clinical-development.pdf, 2019
Medicine, UNLo:ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03541174, 2019
Sidharta PN, Melchior M, Kankam MK, Dingemanse J (2019) Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects. Drug Des Dev Ther 13:949–964
Wenzel RR, Littke T, Kuranoff S et al (2009) Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20:655–664
Smolander J, Vogt B, Maillard M et al (2009) Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin Pharmacol Ther 85:628–634
Mann JFE, Green D, Jamerson K et al (2010) Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21:527–535
de Zeeuw D, Coll B, Andress D et al (2014) The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25:1083–1093. https://doi.org/10.1681/ASN.2013080830
Heerspink HJL, Parving H-H, Andress DL et al (2019) Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393:1937–1947
Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306
Trachtman H, Nelson P, Adler S et al (2018) DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 29:2745–2754
Medicine, UNLo: ClinicalTrials.gov. Study of sparsentan in patients with primary focal segmental glomerulosclerosis (FSGS) (DUPLEX). 2019. https://clinicaltrials.gov/ct2/show/NCT03493685. Accessed 28 Nov 2019
Medicine, UNLo: ClinicalTrials.gov. A study of the effect and safety of sparsentan in the treatment of patients with IgA nephropathy (PROTECT). 2019. https://clinicaltrials.gov/ct2/show/NCT03762850. Accessed 28 Nov 2019
Medicine, UNLo: ClinicalTrials.gov. The role of endthelin-1 in sickle cell disease. 2019. https://clinicaltrials.gov/ct2/show/NCT02712346. Accessed 28 Nov 2019
Battistini B, Berthiaume N, Kelland NF et al (2006) Profile of past and current clinical trials involving endothelin receptor antagonists: the novel “-sentan” class of drug. Exp Biol Med 231:653–695
Hoekman J, Lambers Heerspink HJ, Viberti G et al (2014) Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. Clin J Am Soc Nephrol 9:490–498
Kohan DE, Lambers Heerspink HJ, Coll B et al (2015) Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy. Clin J Am Soc Nephrol 10:1568–1574
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Benigni, A., Buelli, S. & Kohan, D.E. Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition. Pediatr Nephrol 36, 763–775 (2021). https://doi.org/10.1007/s00467-020-04518-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-020-04518-2